NCT02182245已完成1 期
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120
研究概览
简要总结
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma
- •Metastatic disease or locally advanced disease that is not resectable with curative intention
- •Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator
- •Age 18 years or older
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Life expectancy of at least 6 months
- •Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements
排除标准
- •Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
- •Radiotherapy within 4 weeks before the start of therapy
- •Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy
- •Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours
- •Patients with known brain metastases
- •Symptomatic bowel obstruction or known or suspected malabsorption
- •Patients with pericardial effusion which is haemodynamically relevant
- •Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ)
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study medication
- •History of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 6 months
- •Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low dose daily acetylsalicylic acid <300 mg)
- •Major injuries and surgeries within the past 3 weeks, planned surgical procedures during the trial, incomplete wound healing
- •Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their excipients or vehicles such as polyoxyethylated castor oil
- •Clinically significant peripheral polyneuropathy (>CTCAE grade 1) which precludes therapy with paclitaxel
- •Absolute neutrophil count (ANC) <1500/μL, platelet count <100000/μL, or haemoglobin <9 mg/dL
- •Total bilirubin >1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST (Aspartate aminotransferase) >1.5 x the upper limit of normal (ULN)
- •Serum creatinine >1.5 mg/dL (>132 μmol/L)
- •Persistent gross haematuria
- •Pregnancy or breast feeding
- •Women with childbearing potential and who are sexually active and unwilling to use a medically acceptable method of contraception (oral contraceptive, diaphragm with spermicide, intrauterine device, condom with spermicide)
- •Known or suspected active drug or alcohol abuse
研究组 & 干预措施
Combination Therapy
Experimental
干预措施: Paclitaxel (Drug)
Combination Therapy
Experimental
干预措施: BIBF 1120 (Drug)
Combination Therapy
Experimental
干预措施: Carboplatin (Drug)
Monotherapy
Experimental
干预措施: BIBF 1120 (Drug)
结局指标
主要结局
Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120
时间窗: up to 9 months
Maximum tolerated dose (MTD) of BIBF 1120
时间窗: up to 126 days
次要结局
- Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients(up to 9 months)
- Time to tumour progression (time from treatment start to the time of documented tumour progression)(up to 9 months)
- Cancer antigen 125 (CA-125) response(Day 1 of each treatment period)
研究者
相似试验
已完成
1 期
Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02182102Boehringer Ingelheim26
已完成
1 期
An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursTumorsNCT02182206Boehringer Ingelheim50
已完成
1 期
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02182232Boehringer Ingelheim33
终止
1 期
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)Ovarian NeoplasmsNCT01329549Boehringer Ingelheim2
已完成
1 期
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid TumoursMalignant Solid TumourNCT01951846Boehringer Ingelheim61